A randomized, self-controlled study of 0.05% fluticasone propionate cream combined with 0.005% carpotriol ointment or single treatment for mild to moderate plaque psoriasis

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100041678

Enrollment

Unknown

Registered

2021-01-01

Start date

2021-01-15

Completion date

Unknown

Last updated

2021-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

psoriasisi

Interventions

Experimental group:Apply 0.005% carpotriol ointment externally in the morning and 0.05% fluticasone propionate cream externally in the evening

Control group:Apply 0.05% fluticasone propionate cream externally, twice daily

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 65 years; 2. Conform to clinical diagnosis, with psoriasis vulgaris was detected in the plateau, arms and legs have obvious patch shape characteristics, bilateral symmetry; 3. The diameter of target lesion area is more than 2 cm; 4. Psoriasis area and severity score (PASI) 10 points or less, static physicians overall assessment (sPGA) 1 ~ 2 minutes, the affected body surface area (BSA) 10% or less; 5. Skin no bacteria or fungi or signs of infection, virus and other pathogens without leakage, erosion or ulcer; 6. Volunteered for the study, and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Known experimental drug allergies; 2. Severe liver and kidney disease, cardiovascular disease, blood system diseases, autoimmune diseases, severe infections, diabetes, mental illness, etc.; 3. Malignant tumor or other may affect the correct evaluation of curative effect of serious illness; 4. Nearly eight weeks system using biological preparation; 5. Nearly four weeks system used in the treatment of psoriasis drug (including but not limited to, methotrexate, azathioprine, ring spore element, mycophenolate mofetil, tacrolimus, retinoic acid, glucocorticoids), phototherapy, PUVA and Chinese herbal medicine; 6. Nearly 2 weeks local use may affect the assessment of psoriasis topical preparations (including but not limited to, glucocorticoid, vitamin D3 derivatives, this dimension of muhammad, calcineurin inhibitors, salicylic acid, coal tar) 7. Pregnancy, nursing mothers; 8. Psoriatic patients of special positions, such as the scalp, in the face and neck, genital, skin folds, etc.; 9. Allergic to research drugs; 10. Other reasons the researchers considered unsuitable for inclusion.

Design outcomes

Primary

Measure	Time frame
PASI;	—

Countries

China

Contacts

Public ContactLinfeng Li

Beijing Friendship Hospital Capital Medical University

zoonli@sina.com+86 13693620186

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026